ArticleBioMed research international2026
Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Splenic Steatopathy: A Clinical and Experimental Framework for Lipid-Associated Splenic Pathology.Clinical and experimental gastroenterology · 2026Review
- Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinically significant portal hypertension (CSPH) is a major determinant of adverse outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), but reliable noninvasive identification remains challenging. We evaluated whether routinely available ultrasound and clinical variables could help identify CSPH in adults with MASLD.
methodsWe performed a retrospective cohort study of adults with MASLD who underwent HVPG measurement at a tertiary referral centre. Routinely available demographic, laboratory, routine ultrasound and liver stiffness variables were evaluated using logistic regression and internally validated machine learning models to identify CSPH, defined as HVPG ≥ 10 mmHg.
resultsAmong 218 adults with MASLD, 44 (20.2%) had CSPH. Compared with patients without CSPH, those with CSPH showed less favourable noninvasive profiles, particularly in ultrasound- and stiffness-based measures (liver stiffness: 9.2 vs. 7.8 kPa; spleen length: 119.3 vs. 115.0 mm), whereas most routine biochemical markers were broadly similar between groups. Overall predictive performance was modest across all evaluated models; random forest achieved the highest discrimination (AUC = 0.67), followed by SVM (AUC = 0.65) and logistic regression (AUC = 0.604). In multivariable analysis, portal vein calibre (OR = 1.60) and liver stiffness (OR = 1.134) showed the strongest independent associations with CSPH, although overall predictive accuracy remained limited.
conclusionsIn adults with MASLD, routinely available ultrasound and clinical variables showed only modest ability to identify CSPH. Although some noninvasive markers were independently associated with CSPH, model performance was insufficient for stand-alone clinical triage. These findings support further refinement of MASLD-specific noninvasive prediction strategies rather than immediate clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.